arrow
R

Ronglai Shen

Memorial Sloan Kettering Cancer Center
H指数:32
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial

不可切除的III期非小细胞肺癌中,Canakinumab联合化放疗和Durvalumab巩固治疗:CHORUS I/II期试验

2026-09-070
OAAI
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

乳腺癌的同源重组缺陷和半合子驱动抵抗

Nature
IF48.5
2026-03-040
OAAI
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

在去分化脂肪肉瘤中序贯使用CDK4/6和PD-1抑制剂后的肿瘤与免疫动态变化:一项2期研究的结果

2026-02-010
PRE
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

编辑关注声明:同时靶向IGF-1R和ALK在ALK融合阳性肺癌中的合理性

2025-11-200
OAAI
Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma

量化定义的基质B细胞聚集物与不可切除黑色素瘤对检查点抑制剂的应答相关

2025-04-010
OAAI
Automated real-world data integration improves cancer outcome prediction

自动化的真实世界数据集成可改善癌症结果预测

Nature
IF48.5
2024-11-060
OAAI
Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

外周血(PB)T细胞表型和肿瘤微环境(TME)亚型与肉瘤中免疫检查点阻断(ICB)的疗效独立相关

2024-09-010
PRE
Signatures of selection for biallelic inactivation in tumor suppressor genes across cancer types
2024-03-220
PRE
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

循环肿瘤DNA指导治疗晚期非小细胞肺癌的总生存期

2022-11-1068
OA
Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance
2022-02-1517
PRE
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
2021-08-2565
OA